When journalist Jon Gluck learned he had multiple myeloma, doctors told him he had 18 months to live. That was 20 years ago. ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

Merck & Co. Inc. closed 42.70% short of its 52-week high of $134.63, which the company reached on June 25th.

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...